Inovalis Real Estate Investment Trust (TSE:INO – Free Report) – Equities research analysts at Desjardins cut their FY2024 EPS estimates for shares of Inovalis Real Estate Investment Trust in a research note issued to investors on Monday, November 11th. Desjardins analyst A. Leon now forecasts that the company will earn $0.01 per share for the year, down from their prior estimate of $0.06.
Inovalis Real Estate Investment Trust Price Performance
Inovalis Real Estate Investment Trust (TSE:INO – Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported C($0.29) earnings per share (EPS) for the quarter. The business had revenue of C$3.52 million during the quarter.
Inovalis Real Estate Investment Trust Company Profile
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
See Also
- Five stocks we like better than Inovalis Real Estate Investment Trust
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- How to Invest in Blue Chip Stocks
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Inovalis Real Estate Investment Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalis Real Estate Investment Trust and related companies with MarketBeat.com's FREE daily email newsletter.
